|Last Price$90.15||Day Change (%)1.02%|
|Open Price$89.81||Day Change ($)0.91|
|Day Range89.69–90.27||52-Week Range76.36–95.50|
As of Fri 10/24/2014 06:39 PM EST | USD
EU Approves Acquisition of Novartis Animal Health Division by Eli Lilly
ImmunoGen, Inc. Reports First Quarter Fiscal Year 2015 Financial Results
Oxford Biomedica Inks New Collaboration Pact with Novartis
Research and Markets: Global Pancreatic Cancer Market 2014-2018: Key Vendors are Celgene, Eli Lilly, F. Hoffmann-La Roche, Novartis and Pfizer
The company's diverse operating divisions and robust pipeline should lead to steady growth.
Research and Markets: Global Partial Seizure Clinical Trials Review, H2, 2014
Research and Markets: Competitor Analysis: Ebola Virus Vaccines and Therapeutics Report 2014 Featuring Over 30 Institutions
Novartis NVS announced Friday that it is removing Zelnorm for irritable bowel syndrome from the U.S. market at the request of the Food and Drug Administration. We think Zelnorm could eventually return to pharmacy shelves in the United States, but we have drastically reduced our estimate of sales ...
Research and Markets: Global Biological Drugs Market Outlook 2020
Research and Markets: Fallopian Tube Cancer - Pipeline Review, H2 2014